Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ECOZA vs AMPHOTERICIN B
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis
Aspergillosis,Blastomycosis,Candidiasis,Coccidioidomycosis,Cryptococcosis,Histoplasmosis,Mucormycosis,Sporotrichosis,Visceral leishmaniasis,Empiric therapy for febrile neutropenia,Meningitis (cryptococcal, coccidioidal)
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Terminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Not extensively metabolized; minimal systemic absorption after topical application.
Primarily hepatic; exact enzymes not well characterized.
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
Approximately 89–93% bound to plasma proteins, primarily albumin.
90–95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Apparent volume of distribution is approximately 2–3 L/kg, indicating extensive tissue penetration.
4–5 L/kg (extensive tissue binding, especially in liver, spleen, and lungs).
Oral bioavailability is approximately 37% (range 20–70%) due to first-pass metabolism; topical bioavailability is negligible systemically.
IV: 100%; oral: <5%; topical: minimal systemic absorption.
No dosage adjustment required for renal impairment. Systemic absorption is minimal after topical or intravaginal use.
Acute kidney injury: consider dose reduction or switch to liposomal formulation. No specific GFR-based dose adjustments for conventional formulation; monitor renal function and electrolytes. For liposomal amphotericin B, no dosage adjustment required for renal impairment. Continuous renal replacement therapy: conventional amphotericin not recommended due to nephrotoxicity; liposomal preferred.
No dosage adjustment required for hepatic impairment due to minimal systemic absorption.
No specific Child-Pugh based dose adjustments. Use caution in hepatic impairment; monitor liver function tests. Dose adjustment not typically required.
Safety and efficacy in pediatric patients have not been established for vaginal use. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily; duration based on clinical response. Weight-based dosing not applicable.
Conventional amphotericin B: 0.25-1.5 mg/kg/day IV; initial test dose 0.1 mg/kg. Liposomal amphotericin B: 3-5 mg/kg/day IV. For neonates: 1 mg/kg/day. Maximum daily dose: 1.5 mg/kg for conventional, 5 mg/kg for liposomal.
No specific dose adjustment required; use same dosing as for younger adults. Monitor for local irritation or adverse effects.
Use with caution due to age-related renal function decline; monitor renal function and electrolyte levels carefully. Same dosing as adults; adjust for renal impairment if present. Lower doses may be considered based on clinical status.
None
Amphotericin B should be used primarily for progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of fungal disease. It should be used under close medical supervision due to potential toxicity.
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs.
Monitor renal function, electrolytes, and liver function; risk of nephrotoxicity, hypokalemia, hypomagnesemia, and infusion-related reactions; caution in patients with renal impairment and those receiving other nephrotoxic drugs.
Known hypersensitivity to imidazole antifungals or any component of the formulation
Hypersensitivity to amphotericin B or any component of the formulation; unless the potential benefit outweighs the risk.
No clinically significant food interactions for topical econazole nitrate. Avoid alcohol if using oral antifungal concurrently (not applicable here).
Avoid excessive salt intake; monitor for hypokalemia and hypomagnesemia. No specific food restrictions but maintain adequate hydration.
ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topical application, unlikely to cause fetal harm; however, prolonged use near term is not recommended due to theoretical risk of premature ductus arteriosus closure if systemic absorption occurs.
FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Use during pregnancy only if clearly needed. Limited data suggest no increased risk of major malformations across all trimesters.
Not known if econazole is excreted in human milk. M/P ratio not available. Due to low systemic absorption after topical use, risk to nursing infant is considered low. Caution if applied to breast area; avoid infant ingestion.
Excreted in breast milk in low levels; M/P ratio not established. Consideration of benefits vs risks; caution in nursing infants due to potential for oral absorption and adverse effects.
No dose adjustment needed. Pharmacokinetic changes in pregnancy (e.g., increased skin blood flow, hydration) may slightly alter absorption but clinical significance is minimal. Use standard topical dosing as prescribed.
No specific dose adjustments recommended in pregnancy; standard dosing based on indication and patient weight. Pharmacokinetic changes in pregnancy (increased Vd, increased clearance) may theoretically require higher doses, but clinical data insufficient to recommend adjustment.
Ecoza (econazole nitrate) is a topical azole antifungal. Avoid use on open wounds or broken skin. Apply once daily for 4 weeks for tinea pedis; 2 weeks for tinea cruris/corporis. Do not use occlusive dressings. Monitor for local irritation, burning, or allergic contact dermatitis.
Premedicate with acetaminophen, diphenhydramine, and hydrocortisone to reduce infusion-related reactions. Monitor serum potassium and magnesium closely due to renal wasting. Use normal saline bolus before infusion to reduce nephrotoxicity. Lipid formulations allow higher doses with less nephrotoxicity. Amphotericin B deoxycholate is reserved for severe, refractory cases.
Apply a thin layer to cleaned, dry affected area and surrounding skin once daily or as directed.,Wash hands before and after application unless treating hands.,Use for the full prescribed duration even if symptoms improve to prevent recurrence.,Avoid contact with eyes, mouth, or mucous membranes. If contact occurs, rinse with water.,Do not cover the treated area with bandages or wrappings unless instructed by your doctor.,Inform your doctor if symptoms persist after 2 weeks or worsen, or if severe irritation occurs.,Store at room temperature away from moisture and heat.
You may experience fever, chills, and nausea during infusion; these are common and can be managed with premedications.,Report any signs of kidney problems such as decreased urine output, swelling in legs, or fatigue.,Avoid potassium and magnesium supplements unless prescribed, as levels may fluctuate.,This medication can cause low blood pressure during infusion; rise slowly from sitting or lying down.,Complete the full course even if you feel better to prevent the infection from returning.
No interactions on record
"Efinaconazole, a triazole antifungal, inhibits fungal CYP450-dependent lanosterol 14α-demethylase, reducing ergosterol synthesis. Amphotericin B binds to ergosterol in fungal membranes, forming pores that cause cell death. Concomitant use may decrease Amphotericin B efficacy because efinaconazole depletes ergosterol, the target for Amphotericin B, potentially attenuating the polyene's antifungal activity, especially in systemic fungal infections."
"Gentamicin, an aminoglycoside antibiotic, and Amphotericin B, a polyene antifungal agent, both independently induce nephrotoxicity. Concurrent administration synergistically increases the risk of acute kidney injury, characterized by elevated serum creatinine, reduced glomerular filtration rate, and potential tubular necrosis. This additive nephrotoxic effect necessitates cautious use and enhanced monitoring."
"Amphotericin B, a polyene antifungal, can cause hypokalemia and hypomagnesemia due to renal tubular damage. Isradipine, a calcium channel blocker, may also affect electrolyte balance. Concomitant use increases the risk of severe hypokalemia, potentially leading to cardiac arrhythmias, QT prolongation, and neuromuscular effects. Close monitoring of serum electrolytes and ECG is essential."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ECOZA vs AMPHOTERICIN B, answered by our medical review team.
ECOZA is a Topical Antifungal that works by Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.. AMPHOTERICIN B is a Antifungal that works by Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ECOZA and AMPHOTERICIN B depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ECOZA is: For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.. The standard adult dose of AMPHOTERICIN B is: 0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ECOZA and AMPHOTERICIN B in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ECOZA is classified as Category C. ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topic. AMPHOTERICIN B is classified as Category C. FDA Pregnancy Category B. Animal studies show no evidence of fetal harm; no adequate human studies in first trimester. Use during pregnancy only if clearly needed. Limited data sug. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.